Targeting the RAAS for the treatment of atherosclerosis

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 3, 2005, Pages 221-229

  Ferrario, Carlos M ^a   Strawn, William B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; MINERALOCORTICOID ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; RAMIPRIL; RENIN INHIBITOR;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; ELECTRON BEAM TOMOGRAPHY; GENE THERAPY; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VACCINATION;

EID: 27144537733     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.08.008     Document Type: Review

References (40)

1. V. Kon and K. Jabs Angiotensin in atherosclerosis Curr. Opin. Nephrol. Hypertens. 13 2004 291-297
2. B. Pitt A new HOPE for aldosterone blockade? Circulation 110 2004 1714-1716
3. C.M. Ferrario et al. Renin-angiotensin system as a therapeutic target in managing atherosclerosis Am. J. Ther. 11 2004 44-53
4. V. Esteban et al. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells Circ. Res. 96 2005 965-973
5. C.M. Ferrario Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology Curr. Hypertens. Rep. 5 2003 129-134
6. B. Dahlof et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Lancet 359 2002 995-1003
7. C.M. Ferrario The role of angiotensin antagonism in stroke prevention in patients with hypertension: Focus on losartan Curr. Med. Res. Opin. 20 2004 1797-1804
8. R.N. Re Tissue renin angiotensin systems Med. Clin. North Am. 88 2004 19-38
9. M.C. Chappell et al. Novel aspects of the renal renin-angiotensin system: Angiotensin-(1-7), ACE2 and blood pressure regulation Contrib. Nephrol. 143 2004 77-89
10. M. Igase et al. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in aorta of spontaneously hypertensive rats Am. J. Physiol. Heart Circ. Physiol. 289 2005 H1013-H1019
11. K. Allikmets Aliskiren (Speedel) Curr. Opin. Invest. Drugs 3 2002 1479-1482
12. A.H. Gradman et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Circulation 111 2005 1012-1018
13. R. Levi et al. Activation of a renin-angiotensin system in ischemic cardiac sympathetic nerve endings and its association with norepinephrine release Int. Immunopharmacol. 2 2002 1965-1973
14. S. Takai et al. Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis Eur. J. Pharmacol. 501 2004 1-8
15. Y. Uehara et al. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta Cardiovasc. Res. 55 2002 870-876
16. S. Keidar et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone Circulation 109 2004 2213-2220
17. S. Keidar et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice J. Cardiovasc. Pharmacol. 41 2003 955-963
18. S. Rajagopalan et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis Circulation 105 2002 2212-2216
19. B. Pitt Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: Implications of the RALES and EPHESUS studies Mol. Cell Endocrinol. 217 2004 53-58
20. S. Wassmann et al. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice Circulation 110 2004 3062-3067
21. A. Daugherty et al. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor Circulation 110 2004 3849-3857
22. C.M. Ferrario Use of angiotensin II receptor blockers in animal models of atherosclerosis Am. J. Hypertens. 15 2002 9S-13S
23. E. Lonn et al. Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) Circulation 103 2001 919-925
24. S.E. Nissen et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial J. Am. Med. Assoc. 292 2004 2217-2225
25. E. Shinoda et al. Quantitative coronary angiogram analysis: Nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study) Hypertension 45 2005 1153-1158
26. M.H. Olsen et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy Blood Press. 14 2005 177-183
27. P.S. Sever et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial Lancet 361 2003 1149-1158
28. F. Cipollone et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity Circulation 109 2004 1482-1488
29. M. Fukuhara et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis Hypertension 35 2000 353-359
30. M.T. Johnstone et al. Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model Circulation 110 2004 2060-2065
31. S. Dimmeler and A.M. Zeiher Vascular repair by circulating endothelial progenitor cells: The missing link in atherosclerosis? J. Mol. Med. 82 2004 671-677
32. W.B. Strawn et al. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells Br. J. Haematol. 126 2004 120-126
33. R.S. Richmond et al. Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells J. Renin Angiotensin Aldosterone Syst. 5 2004 176-182
34. T. Imanishi et al. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress J. Hypertens. 23 2005 97-104
35. T.Q. Min et al. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease Cardiovasc. Drugs Ther. 18 2004 203-209
36. B.J. Morris The scorching breath of angiotensin J. Hypertens. 23 2005 33-35
37. S.V. Pinheiro et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney Hypertension 44 2004 490-496
38. A. Maeda et al. Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)gamma Cell Biol. Int. 29 2005 422-428
39. R. Clasen et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin Hypertension 46 2005 137-143
40. W.B. Strawn et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia Circulation 101 2000 1586-1593